Skip to main content

Table 2 Third-line treatment per study arm

From: A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

 

DC (%)

D (%)

p-value

No treatment

27 (40.3%)

34 (52.3%)

0.222

Chemotherapy

28 (41.8%)

28 (43.1%)

0.999

EGFR-TKIs*

12 (17.9%)

3 (4.6%)

0.026

  1. *Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us